Exploration and Outlook of Recent Applications of Paclitaxel in Breast Cancer Treatment
DOI:
https://doi.org/10.54097/y3qyk117Keywords:
Breast Cancer, Paclitaxel, Nanoformulations.Abstract
Breast cancer, as the most common malignancy in women worldwide, compels enormous efforts in therapeutic research. Paclitaxel, a microtubule stabiliser, has shown its versatility and efficacy in treating various breast cancer subtypes. However, its use is often associated with dose-dependent toxicity and tumour cell resistance. Recent advances in nanotechnology have opened new avenues for delivering paclitaxel, offering potential solutions to these problems. This study aims to summarise paclitaxel's latest applications and prospects in breast cancer treatment, focusing on nanoformulations. The research methods include reviewing and analyzing the latest data from preclinical testing of nano-paclitaxel formulations and their evaluation in clinical practice. In addition, paclitaxel's mechanism of action, clinical application, main side effects, and development of its nano-formulations are also extensively discussed. This paper thoroughly summarises the present condition and prospects of using paclitaxel for treating breast cancer, especially nanoformulations. It also highlights the need for continued research and development to improve the efficacy of paclitaxel and reduce its consequences to serve breast cancer patients better.
Downloads
References
Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249.
Abu Samaan T M, Samec M, Liskova A, et al. Paclitaxel’s mechanistic and clinical effects on breast cancer. Biomolecules, 2019, 9(12): 789.
Weaver B A. How Taxol/paclitaxel kills cancer cells. Molecular Biology of the Cell, 2014, 25(18): 2677-2681.
A'hern R P, Jamal-Hanjani M, Szász A M, et al. Taxane benefits in breast cancer—a role for grade and chromosomal stability. Nature Reviews Clinical Oncology, 2013, 10(6): 357-364.
Sánchez J C, Muñoz L V, Galindo-Márquez, et al. Paclitaxel Regulates TRPA1 Function and Expression Through PKA and PKC. Neurochemical Research, 2023, 48(1): 295-304.
Asghari F, Haghnavaz N, Shanehbandi D, et al. Differentially altered expression of let-7a and miR-205 tumour-suppressor miRNAs in different breast cancer subtypes under treatment with Taxol. Advances in Clinical & Experimental Medicine, 2018, 27(7): 941-945.
Wanderley C W, Colon D F, Luiz J P M, et al. Paclitaxel reduces tumour growth by reprogramming tumour-associated macrophages to an M1 profile in a TLR4-dependent manner. Cancer Research, 2018, 78(20): 5891-5900.
Larionova I, Cherdyntseva N, Liu T, et al. Interaction of tumour-associated macrophages and cancer chemotherapy. Oncoimmunology, 2019, 8(7): e1596004.
Baghaee P T, Donya A. Review of studies on the effects of nanotechnology on breast cancer. arXiv preprint arXiv, 2018: 1812.07494.
Waks A G, Winer E P. Breast cancer treatment: a review. JAMA, 2019, 321(3): 288-300.
Watt A C, Goel S. Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in treating hormone receptor-positive breast cancer. Breast Cancer Research, 2022, 24(1): 1-11.
Gianni L, Mansutti M, Anton A, et al. Comparing neoadjuvant nab-paclitaxel vs paclitaxel, both followed by anthracycline regimens in women with ERBB2/HER2-negative breast cancer—the evaluating treatment with neoadjuvant Abraxane (ETNA) trial: a randomised phase 3 clinical trial. JAMA Oncology, 2018, 4(3): 302-308.
Diamond J R, Becerra C, Richards D, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Research and Treatment, 2020, 184: 53-62.
Miles D, Cameron D, Bondarenko I, et al. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. European Journal of Cancer, 2017, 70: 146-155.
Masuda N, Toi M, Yamamoto N, et al. Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial. Breast Cancer, 2018, 25: 407-415.
Perez E A, Romond E H, Suman V J, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology, 2014, 32(33): 3744.
Luo C, Wang P, He S, et al. Progress and prospect of immunotherapy for triple-negative breast cancer. Frontiers in Oncology, 2022, 12: 919072.
Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Annals of Oncology, 2019, 30(8): 1279-1288.
Schmid P, Adams S, Rugo H S, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. New England Journal of Medicine, 2018, 379(22): 2108-2121.
Salehifar E, Janbabaei G, Hendouei N, et al. Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy: a randomised controlled trial. Clinical Drug Investigation, 2020, 40: 249-257.
Werida R H, Elshafiey R A, Ghoneim A, et al. Role of alpha-lipoic acid in counteracting paclitaxel-and doxorubicin-induced toxicities: A randomised controlled trial in breast cancer patients. Supportive Care in Cancer, 2022, 30(9): 7281-7292.
Chen Q, Xu S, Liu S, et al. Emerging nanomedicines of paclitaxel for cancer treatment. Journal of Controlled Release, 2022, 342: 280-294.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
